These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29184)

  • 21. Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia.
    Davila R; Gonzalez MA; Zumarraga M; Andia I; Guimon J; Silva RR; Friedhoff AJ
    Biol Psychiatry; 1995 Aug; 38(4):267-9. PubMed ID: 8547450
    [No Abstract]   [Full Text] [Related]  

  • 22. The relative role of dopamine and norepinephrine receptor blockade in the action of antipsychotic drugs: metoclopramide, thiethylperazine, and molindone as pharmacological tools.
    Robinson SE; Berney S; Mishra R; Sulser F
    Psychopharmacology (Berl); 1979 Aug; 64(2):141-7. PubMed ID: 40288
    [No Abstract]   [Full Text] [Related]  

  • 23. [Dopamine hypothesis in schizophrenia--recent findings in limbic system abnormality].
    Toru M; Watanabe S; Kaneno S
    Nihon Rinsho; 1978; 36(1):76-82. PubMed ID: 24768
    [No Abstract]   [Full Text] [Related]  

  • 24. A critical appraisal of CSF monoamine metabolite studies in schizophrenia.
    Widerlöv E
    Ann N Y Acad Sci; 1988; 537():309-23. PubMed ID: 2462396
    [No Abstract]   [Full Text] [Related]  

  • 25. Neuroleptic-induced supersensitivity psychosis.
    Chouinard G; Jones BD; Annable L
    Am J Psychiatry; 1978 Nov; 135(11):1409-10. PubMed ID: 30291
    [No Abstract]   [Full Text] [Related]  

  • 26. Concentrations of monoamine metabolites and chlorpromazine in cerebrospinal fluid for prediction of therapeutic response in psychotic patients treated with neuroleptic drugs.
    Sedvall G
    Prog Biochem Pharmacol; 1980; 16():133-40. PubMed ID: 6160594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute administration of alprazolam has no effect on plasma homovanillic acid concentration in normal subjects.
    Zemishlany Z; Davidson M; Jaff S; McQueeney R
    Schizophr Res; 1991; 5(1):81-3. PubMed ID: 1677266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipsychotic efficacy of clozapine in correlation to changes in catecholamine metabolism in man.
    Ackenheil M; Beckmann H; Greil W; Hoffmann G; Markianos E; Raese J
    Adv Biochem Psychopharmacol; 1974; 9(0):647-57. PubMed ID: 4836227
    [No Abstract]   [Full Text] [Related]  

  • 29. Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (D1, D3, D4) and 5-HT2a receptors.
    Harrison PJ
    Br J Psychiatry Suppl; 1999; (38):12-22. PubMed ID: 10884896
    [No Abstract]   [Full Text] [Related]  

  • 30. Prediction of response to neuroleptic drug therapy in schizophrenia.
    Awad AG
    Can J Psychiatry; 1985 Jun; 30(4):241-2. PubMed ID: 2861885
    [No Abstract]   [Full Text] [Related]  

  • 31. Seroquel: a putative atypical antipsychotic drug with serotonin- and dopamine-receptor antagonist properties. Preclinical and early clinical trials in schizophrenia.
    J Clin Psychiatry; 1995 Sep; 56(9):438-45. PubMed ID: 7665549
    [No Abstract]   [Full Text] [Related]  

  • 32. Influence of -141C Ins/Del Polymorphism in DRD2 Gene on Clinical Symptoms and Plasma Homovanillic Acid Levels in the Treatment of Schizophrenia With Aripiprazole.
    Miura I; Kanno-Nozaki K; Hino M; Horikoshi S; Ota T; Mashiko H; Niwa S; Yabe H
    J Clin Psychopharmacol; 2015 Jun; 35(3):333-4. PubMed ID: 25871573
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug treatment of schizophrenia.
    Silverstone T
    N Z Med J; 1994 Apr; 107(976):145-6. PubMed ID: 7909363
    [No Abstract]   [Full Text] [Related]  

  • 34. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia.
    Pilowsky LS; Costa DC; Ell PJ; Murray RM; Verhoeff NP; Kerwin RW
    Lancet; 1992 Jul; 340(8813):199-202. PubMed ID: 1353135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Practical issues in clinical research of schizophrenia.
    Brunello N; Judd LL; Langer SZ; Mendlewicz J; Racagni G
    Neuropsychobiology; 1997; 35(2):57-60. PubMed ID: 9097292
    [No Abstract]   [Full Text] [Related]  

  • 36. The effect of propranolol on CSF amine metabolites in psychiatric patients.
    King DJ; Cooper SJ; Liddle J
    Br J Clin Pharmacol; 1983 Mar; 15(3):331-7. PubMed ID: 6189502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Schizophrenia and dopamine (author's transl)].
    Toru M
    Tanpakushitsu Kakusan Koso; 1978; 23(4):303-16. PubMed ID: 26107
    [No Abstract]   [Full Text] [Related]  

  • 38. Smooth pursuit eye movements, clinical symptoms, CSF metabolites, and skin conductance habituation in schizophrenic patients.
    Bartfai A; Levander SE; Sedvall G
    Biol Psychiatry; 1983 Sep; 18(9):971-87. PubMed ID: 6196060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospects for pharmacotherapy of schizophrenia.
    Pickar D
    Lancet; 1995 Mar; 345(8949):557-62. PubMed ID: 7539875
    [No Abstract]   [Full Text] [Related]  

  • 40. Is there a presynaptic tardive dyskinesia?
    Bowers MB; Glazer WM
    J Clin Psychopharmacol; 1987 Feb; 7(1):57-9. PubMed ID: 2880877
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.